Table 1.

COVID-19 Vaccine uptake by participant characteristics

	All responders n = 259	Vaccinated n = 219, 84.5%	Unvaccinated n = 27, 10.4%	PNTA* n = 3, 1.1%	Missing n = 10, 4%
Age, mean (SD), year	46.8 (14.0)	48.4(13.8)	34.0 (7.7)	37.0 (7.2)	47.1(15.6)
Age ≥ 40 years old	175	162 (92.6)	5 (2.9)	1 (0.6)	7 (4.0)
Sex
Female	69	57 (82.6)	9 (13.0)	1 (1.4)	2 (2.9)
Male	189	162 (85.7)	18 (9.5)	2 (1.1)	7 (3.7)
Highest education level
Less than HS**	5	4 (80.0)	1 (20.0)	0 (0.0)	0 (0.0)
Some/completed HS	55	36 (65.5)	14 (25.5)	1 (1.8)	4 (7.3)
Some/completed university	150	137 (91.3)	6 (4.0)	2 (1.3)	5 (3.3)
Some/completed graduate education	47	41 (87.2)	6 (12.8)	0 (0.0)	0 (0.0)
Total household income
$29,999 under	83	71 (85.5)	7 (8.4)	1 (1.2)	4 (4.8)
$30,000–59,999	77	64 (83.1)	10 (13.0)	1 (1.3)	2 (2.6)
$60,000 to 89,999	36	29 (80.6)	6 (16.7)	1 (2.8)	0 (0.0)
$90,000 and up	47	41 (87.2)	3 (6.4)	0 (0.0)	3 (6.4)
Current employment status
Employed	139	120 (86.3)	16 (11.5)	1 (0.7)	2 (1.4)
Unemployed	113	95 (84.1)	10 (8.8)	1 (0.9)	7 (6.2)
Born in Canada	165	132 (80.0)	25 (15.2)	2 (1.2)	6 (3.6)
Inject drugs user	17	14 (82.4)	2 (11.8)	1 (5.9)	0 (0.0)
Non-prescription illicit drug user	31	29 (93.5)	0 (0.0)	1 (3.2)	1 (3.2)
Gender
Woman	66	53 (80.3)	10 (15.2)	1 (1.5)	2 (3.0)
Man	163	139 (85.3)	17 (10.4)	2 (1.2)	5 (3.1)
Transgender	2	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
Two-spirit	9	7 (77.8)	0 (0.0)	0 (0.0)	2 (22.2)
Queer	12	12 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
Non-binary	4	4 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
Agender	0	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other	1	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
MSM***	164	141 (86.0)	17 (10.4)	1 (0.6)	5 (3.0)
Ethnicity
White	139	115 (82.7)	20 (14.4)	1 (0.7)	3 (2.2)
BIPOC	115	100 (87.0)	7 (6.1)	2 (1.7)	6 (5.2)
Ethnicity subgroup
African, Caribbean or Black community	30	26 (86.7)	1 (3.3)	0 (0.0)	3 (10.0)
Person from the Indigenous community	12	11 (91.7)	1 (8.3)	0 (0.0)	0 (0.0)
Migrant	13	13 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
Received HIV diagnosis
≤ 4 years ago	38	27 (71.1)	10 (26.3)	0 (0.0)	1 (2.6)
5–9 years ago	37	23 (62.2)	12 (32.4)	1 (2.7)	1 (2.7)
10–14 years ago	41	37 (90.2)	3 (7.3)	0 (0.0)	1 (2.4)
≥ 15 years ago	134	126 (94.0)	2 (1.5)	2 (1.5)	4 (3.0)
On AVR**** medication	253	215 (85.0)	27 (10.7)	3 (1.2)	8 (3.2)
Comorbidity
Hepatitis C	14	8 (57.1)	5 (35.7)	1 (7.1)	0 (0.0)
Diabetes	38	29 (76.3)	7 (18.4)	1 (2.6)	1 (2.6)
Kidney failure	14	5 (35.7)	8 (57.1)	1 (7.1)	0 (0.0)
Chronic liver disease	15	9 (60.0)	6 (40.0)	0 (0.0)	0 (0.0)
Chronic lung disease	17	12 (70.6)	5 (29.4)	0 (0.0)	0 (0.0)
Severe asthma	20	17 (85.0)	3 (15.0)	0 (0.0)	0 (0.0)
Smoking
Yes	57	46 (80.7)	8 (14.0)	2 (3.5)	1 (1.8)
Not currently/in the past	96	84 (87.5)	9 (9.4)	1 (1.0)	2 (2.1)
Never	97	86 (88.7)	9 (9.3)	0 (0.0)	2 (2.1)
Vaping
Yes	32	24 (75.0)	7 (21.9)	0 (0.0)	1 (3.1)
Not currently/in the past	36	27 (75.0)	7 (19.4)	2 (5.6)	0 (0.0)
Never	182	165 (90.7)	12 (6.6)	1 (0.5)	4 (2.2)
Smoking cannabis
Yes	65	57 (87.7)	5 (7.7)	0 (0.0)	3 (4.6)
Not currently/in the past	80	68 (85.0)	10 (12.5)	2 (2.5)	0 (0.0)
Never	101	86 (85.1)	12 (11.9)	1 (1.0)	2 (2.0)
Consumption of cannabis or cannabinoid-based products (form other than smoking)
Yes	58	49 (84.5)	6 (10.3)	1 (1.7)	2 (3.4)
Not currently/in the past	62	53 (85.5)	8 (12.9)	1 (1.6)	0 (0.0)
Never	128	111 (86.7)	13 (10.2)	1 (0.8)	3 (2.3)

Legend: Data presented as n(%),* PREFER NOT TO ANSWER, **HS = high school, ***MSM = men having sex with men, percent represented as MSM/males, ****AVR = antiviral therapy